SCHEMBL24484263

SCHEMBL24484263

FC1(Cc2cnccn2)CCNCC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 9/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 9/20 0.36
SYK P43405 2/20 0.33
KCNH2 Q12809 2/20 0.31
NISCH Q9Y2I1 1/20 0.31
CHRM1 P11229 1/20 0.31
HTR2A P28223 1/20 0.31
ROCK2 O75116 1/20 0.30
ROCK1 Q13464 1/20 0.30
CDC42BPB Q9Y5S2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30
PIM1 P11309 1/20 0.30
LRRK2 Q5S007 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRNA4 P43681 1/20 0.30
KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26081143 0.83 HRH1 (0.37) HRH1CYP3A4CYP2D6KCNH2CHRM1
SCHEMBL23083679 0.78 KDM4E (0.33) CYP2D6SYKALDH1A1HPGD
SCHEMBL24484270 0.77 CYP2D6 (0.32) HRH1CYP3A4CYP2D6ALDH1A1HSD17B10
SCHEMBL26081848 0.76 TACR1 (0.31) KCNH2
Hydrochloric Acid SCHEMBL25402688 0.75 SLC6A4 (0.43) HRH1CYP3A4CYP2D6ALDH1A1HPGD
SCHEMBL24484693 0.75 KDM1A (0.32) KDM1A
SCHEMBL24484265 0.74 HRH1 (0.39) HRH1CYP3A4CYP2D6KCNH2CHRM1
SCHEMBL24484692 0.74 LRRK2 (0.37) SYKKCNH2LRRK2
SCHEMBL24484733 0.72 DAO (0.35) PIM1LRRK2KDM1A
SCHEMBL26081076 0.72 USP2 (0.37) CYP3A4CYP2D6KCNH2LRRK2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022115620-A1 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SAGE THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed